MedAdvisor Limited

ASX:MDR Rapport sur les actions

Capitalisation boursière : AU$245.3m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

MedAdvisor Croissance future

Future contrôle des critères 4/6

MedAdvisor devrait augmenter ses bénéfices et son chiffre d'affaires de 121.1% et de 16.6% par an respectivement. Le BPA devrait croître de de 122.4% par an. Le rendement des capitaux propres devrait être 10.9% dans 3 ans.

Informations clés

121.1%

Taux de croissance des bénéfices

122.4%

Taux de croissance du BPA

Healthcare Services croissance des bénéfices22.3%
Taux de croissance des recettes16.6%
Rendement futur des capitaux propres10.9%
Couverture par les analystes

Low

Dernière mise à jour25 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Jun 26
Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Apr 24
Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Mar 20
Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Dec 15
Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Apr 20
Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Jun 29
MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09
Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11
Is MedAdvisor (ASX:MDR) A Risky Investment?

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08
Is MedAdvisor (ASX:MDR) Using Too Much Debt?

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10
MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18
What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22
The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18
What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Nov 22
Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Prévisions de croissance des bénéfices et des revenus

ASX:MDR - Estimations futures des analystes et données financières antérieures (AUD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
6/30/20261651213153
6/30/20251443793
6/30/20241211773
12/31/2023109-9-7-6N/A
9/30/2023104-10-4-4N/A
6/30/202398-11-2-1N/A
3/31/202396-877N/A
12/31/202293-51616N/A
9/30/202280-1188N/A
6/30/202268-17-10N/A
3/31/202266-16-6-5N/A
12/31/202164-14-11-11N/A
9/30/202152-14-12-12N/A
6/30/202139-14-13-13N/A
3/31/202128-13-10-9N/A
12/31/202018-12-6-6N/A
9/30/202014-11-8-7N/A
6/30/202010-10-9-9N/A
3/31/20209-9-9-8N/A
12/31/20199-9-8-8N/A
9/30/20199-8-8-7N/A
6/30/20198-8-7-7N/A
3/31/20198-7-6-6N/A
12/31/20187-7-6-5N/A
9/30/20187-6-5-4N/A
6/30/20187-4-4-3N/A
3/31/20186-4-5-3N/A
12/31/20176-4-6-3N/A
9/30/20175-4N/A-3N/A
6/30/20174-3N/A-2N/A
3/31/20173-4N/A-3N/A
12/31/20162-4N/A-3N/A
9/30/20162-4N/A-3N/A
6/30/20161-3N/A-3N/A
3/31/20161-2N/A-2N/A
12/31/20152-1N/A-1N/A
9/30/20152-1N/A-1N/A
6/30/20152-1N/A0N/A
6/30/20141-1N/A-1N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MDR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Bénéfices vs marché: MDR is forecast to become profitable over the next 3 years, which is considered above average market growth.

Croissance élevée des bénéfices: MDR is expected to become profitable in the next 3 years.

Chiffre d'affaires vs marché: MDR's revenue (16.6% per year) is forecast to grow faster than the Australian market (5.4% per year).

Croissance élevée des revenus: MDR's revenue (16.6% per year) is forecast to grow slower than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de MDR devrait être faible dans 3 ans ( 10.9 %).


Découvrir les entreprises en croissance